April 5, 2021 -- Berkeley Lights has launched Opto Assure, a series of assays that provides yield and product quality data during the early stages of cell line development.
Antibody-based therapeutics are prone to quality issues, including aggregation, byproducts, and post-translational modifications, that can negatively affect manufacturability, shelf life, and safety. The series provides direct detection of product aggregates, enabling a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process, the company said.
With Opto Assure, customers will be able to rapidly select clonal cell lines with favorable manufacturability profiles, ultimately reducing scale-up costs and improving downstream products, Berkeley Lights noted.
Copyright © 2021 scienceboard.net